CVC, a leading global private market manager, announces to KKR that it has signed a final agreement for the sale of a majority stake in CVC Asia V of India's leading healthcare organization Healthcare Global Enterprises (“HCG”). I will. CVC Asia V will sell 54% of HCG's stake to funds purchased by KKR, a leading global investment company, at a purchase price of 445/445 per share.
After the transaction is completed, HCG founder Dr. BS Ajai Kumar will assume the role of non-executive chairman and focus on driving excellence in clinical, academic and R&D.
Founded in 1989, HCG is one of India's largest chain of oncology hospitals. HCG operates 25 medical centres in 19 cities with best-in-class infrastructure including 2,500 beds, almost 100 operating theatres and 40 linear accelerator machines (LINACs). Since CVC Asia v invested in 2020, CVC's Indian team has worked closely with HCG in a transformative value creation program to drive revenue growth beyond Covid, improving key performance indicators, Performing source and digital conversions, ensuring continuous improvement for patients. Care and clinical outcomes.
“We are committed to providing a range of services to our customers,” said Siddharth Patel, Managing Partner at CVC. “We are proud to build it into one of India's leading healthcare institutions and make it a reality in time to bring high quality care to many patients over the years.”
